Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LQDA 
Liquidia Technologies Inc (LQDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: LQDA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $30.3
1 Year Target Price $30.3
| 6 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 49.33% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.04B USD | Price to earnings Ratio - | 1Y Target Price 30.3 |
Price to earnings Ratio - | 1Y Target Price 30.3 | ||
Volume (30-day avg) 10 | Beta 0.04 | 52 Weeks Range 8.26 - 19.41 | Updated Date 07/3/2025 |
52 Weeks Range 8.26 - 19.41 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1135.42% |
Management Effectiveness
Return on Assets (TTM) -37.66% | Return on Equity (TTM) -203.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1009705216 | Price to Sales(TTM) 73.67 |
Enterprise Value 1009705216 | Price to Sales(TTM) 73.67 | ||
Enterprise Value to Revenue 71.39 | Enterprise Value to EBITDA -9.43 | Shares Outstanding 85484496 | Shares Floating 66176990 |
Shares Outstanding 85484496 | Shares Floating 66176990 | ||
Percent Insiders 13.64 | Percent Institutions 65.04 |
Upturn AI SWOT
Liquidia Technologies Inc
Company Overview
History and Background
Liquidia Technologies Inc. was founded in 2004. It is a biopharmaceutical company focused on the development and commercialization of novel products that address unmet needs in pulmonary hypertension and other applications. The company utilizes its proprietary PRINTu00ae technology to create particles with precise size, shape, and composition, enabling the development of innovative therapies.
Core Business Areas
- Pulmonary Hypertension: Focuses on developing and commercializing inhaled therapies for the treatment of pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH).
- PRINTu00ae Technology Platform: Leverages the PRINTu00ae (Particle Replication In Non-wetting Templates) technology to engineer particles with specific characteristics for targeted drug delivery.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, CMO, and other key executives. The company's structure includes departments for research and development, clinical operations, manufacturing, commercialization, and administrative functions.
Top Products and Market Share
Key Offerings
- Yutrepia (treprostinil) inhalation powder: Yutrepia is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH). It is a key product based on Liquidia's PRINTu00ae technology. Market share is still developing as it gains traction post-approval. Competitors include United Therapeutics (UTHR) with Tyvaso DPI, and liquid nebulized treprostinil options.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Pulmonary hypertension treatment is a growing market with increasing awareness and diagnostic rates.
Positioning
Liquidia is positioned as an innovative company leveraging its PRINTu00ae technology to develop differentiated therapies in the pulmonary hypertension space, competing against established players and generic alternatives.
Total Addressable Market (TAM)
The global pulmonary hypertension market is estimated to be worth billions of dollars annually. Liquidia is targeting a portion of this market through its inhaled treprostinil product, Yutrepia. Liquidia is positioned to potentially capture a significant segment through ease of use and improved tolerability.
Upturn SWOT Analysis
Strengths
- Proprietary PRINTu00ae technology platform
- Yutrepia approved by FDA
- Potential for improved drug delivery and efficacy
- Focus on unmet medical needs
Weaknesses
- Reliance on single key product (Yutrepia)
- Commercialization challenges against established competitors
- Dependence on regulatory approvals
- Limited financial resources compared to larger pharma companies
Opportunities
- Expansion into other therapeutic areas using PRINTu00ae technology
- Partnerships and collaborations with larger pharmaceutical companies
- Further development of Yutrepia for other indications
- Growing market for pulmonary hypertension therapies
Threats
- Competition from established pharmaceutical companies
- Generic entry eroding market share
- Regulatory hurdles and delays
- Product liability risks
Competitors and Market Share
Key Competitors
- UTHR
Competitive Landscape
Liquidia has a differentiated product with Yutrepia but faces strong competition from United Therapeutics (UTHR) and others. Liquidia's PRINT technology offers potential advantages in drug delivery.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is linked to FDA approvals and market penetration of Yutrepia.
Future Projections: Future projections depend on Yutrepia sales, partnerships, and pipeline development.
Recent Initiatives: Recent initiatives include the commercial launch of Yutrepia and ongoing clinical trials.
Summary
Liquidia Technologies is a biopharmaceutical company focused on pulmonary hypertension, particularly PAH. Its key product, Yutrepia, leverages its PRINTu00ae technology. The company's strengths include its novel technology and approved product, but it faces challenges related to commercialization, competition, and financial resources. The company has the potential for growth through expansion into other indications and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liquidia Technologies Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 2018-07-26 | CEO & Director Dr. Roger A. Jeffs Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 170 | Website https://www.liquidia.com |
Full time employees 170 | Website https://www.liquidia.com | ||
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.